Sonnet BioTherapeutics, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Technology
    • Overview
    • Platform
    • Strategy
    • Progress
    • Publications
  • Pipeline
    • Overview
    • Clinical Trials
  • Partnering
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Dec 17, 2020 6:30am EST

Sonnet BioTherapeutics Provides Fiscal Year 2020 Business and Earnings Update

Nov 30, 2020 8:30am EST

Sonnet BioTherapeutics Announces the Completion of a Successful Non-Human Primate Study of SON-1010

Sep 01, 2020 8:30am EDT

Sonnet Announces New Preclinical Data for SON-1010 (Interleukin 12-F(H)AB)

Aug 25, 2020 7:30am EDT

Sonnet BioTherapeutics Receives $10.5 Million from Exercise of Series A Warrants

Aug 14, 2020 7:30am EDT

Sonnet BioTherapeutics Provides Fiscal Year Third Quarter Business and Earnings Update

Aug 04, 2020 7:35am EDT

Sonnet BioTherapeutics Announces At-The-Market Warrant Repricing and Exchange Resulting in Expected Gross Proceeds to the Company of up to $10.5 Million

Aug 04, 2020 7:30am EDT

Sonnet BioTherapeutics Signs Letter of Intent for Potential Licensing of Neuropathies Asset to New Life Therapeutics

Jul 20, 2020 7:30am EDT

Sonnet Biotherapeutics Announces Positive Preclinical Results from an Initial Efficacy Study Exploring the Combination of Granulocyte-Macrophage Colony-Stimulating Factor with Interleukins 18 and 12

Jul 15, 2020 7:30am EDT

Sonnet BioTherapeutics to Present at the 2020 BTIG Virtual Biotechnology Conference

May 18, 2020 7:30am EDT

Sonnet BioTherapeutics Holdings Provides Business and Earnings Update

RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    Next
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
    © 2023 Sonnet BioTherapeutics, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap